Update for investors of $BIOCON

$BIOCON is currently trading at Rs. 423.70, up by 0.35 points or 0.08% from its previous closing of Rs. 423.35 on the BSE. The scrip opened at Rs. 425.05 and has touched a high and low of Rs. 428.40 and Rs. 419.60 respectively. So far 64063 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 440.30 on 26-May-2026 and a 52 week low of Rs. 331.00 on 11-Aug-2025. Last one week high and low of the scrip stood at Rs. 432.00 and Rs. 409.75 respectively. The current market cap of the company is Rs. 68491.46 crore. The promoters holding in the company stood at 44.91%, while Institutions and Non-Institutions held 31.59% and 23.49% respectively. Biocon’s long-standing partner -- Duopharma Biotech Berhad (Duopharma Biotech) has secured multiple insulin contracts from the Ministry of Health (MoH), Malaysia, valued at over 225 million Malaysian ringgit this year. Duopharma Biotech has secured the contracts through its wholly-owned subsidiary -- Duopharma (M) Sendirian Berhad. As part of these contracts, the company’s subsidiary -- Biocon Sdn. Bhd., Malaysia, will supply short-acting recombinant human insulin, insulin glargine and insulin aspart to Duopharma (M) Sendirian Berhad for distribution, supporting continued access to high-quality, cost-effective insulin therapies for people living with diabetes in Malaysia. Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.